Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.
2/5 보강
TL;DR
A new GPC3-targeted immunoPET radiotracer for noninvasive visualization of GPC3 expression and a first-in-human, proof-of-concept evaluation in patients with HCC demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: HCC to assess its clinical feasibility
I · Intervention 중재 / 시술
[Ga]Ga-aGPC3-Fab PET imaging
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CLINICAL TRIAL REGISTRATION] ClinicalTrials.gov, NCT06383520. Registered on April 25, 2024 ( https://clinicaltrials.gov/study/NCT06383520 ).
OpenAlex 토픽 ·
Hepatocellular Carcinoma Treatment and Prognosis
Nanoplatforms for cancer theranostics
Photoacoustic and Ultrasonic Imaging
A new GPC3-targeted immunoPET radiotracer for noninvasive visualization of GPC3 expression and a first-in-human, proof-of-concept evaluation in patients with HCC demonstrated a favorable safety profil
APA
Zhaoguo Lin, Wenzhu Hu, et al. (2026). Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.. European journal of nuclear medicine and molecular imaging, 53(6), 3891-3903. https://doi.org/10.1007/s00259-025-07739-5
MLA
Zhaoguo Lin, et al.. "Glypican-3-targeted immunoPET imaging of hepatocellular carcinoma: a translational study.." European journal of nuclear medicine and molecular imaging, vol. 53, no. 6, 2026, pp. 3891-3903.
PMID
41688850 ↗
Abstract 한글 요약
[PURPOSE] Accurate diagnosis of hepatocellular carcinoma (HCC) remains a clinical challenge. Glypican-3 (GPC3) is highly expressed in HCC but not in normal liver tissue, making it a promising target for PET-based molecular imaging, which may complement existing approaches for HCC diagnosis. In this study, we developed a new GPC3-targeted immunoPET radiotracer for noninvasive visualization of GPC3 expression and conducted a first-in-human, proof-of-concept evaluation in patients with HCC to assess its clinical feasibility.
[METHODS] An anti-GPC3 antigen-binding fragment (Fab) was generated under Good Manufacturing Practice conditions and labeled with Gallium-68 (Ga) to obtain [Ga]Ga-aGPC3-Fab. In vitro assays, small-animal PET/CT scans, and ex vivo biodistribution experiments were conducted to examine its GPC3 targeting ability. Five patients with radiologically suspected or diagnosed HCC were enrolled in a pilot clinical study and underwent [Ga]Ga-aGPC3-Fab PET imaging. Radiotracer uptake in tumor and non-tumor tissues was quantitatively analyzed.
[RESULTS] [Ga]Ga-aGPC3-Fab was synthesized with high radiochemical purity and demonstrated strong affinity and efficient internalization in GPC3-positive cells. It enabled clear tumor visualization in both subcutaneous and orthotopic GPC3-positive HCC mouse models. All five patients tolerated the PET procedure well, with no adverse effects. [Ga]Ga-aGPC3-Fab successfully detected intrahepatic metastases approximately 1 cm in diameter with high imaging contrast, including lesions that missed on magnetic resonance imaging.
[CONCLUSION] [Ga]Ga-aGPC3-Fab demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions. It may serve as a complementary approach to conventional imaging to improve the diagnostic accuracy of HCC.
[CLINICAL TRIAL REGISTRATION] ClinicalTrials.gov, NCT06383520. Registered on April 25, 2024 ( https://clinicaltrials.gov/study/NCT06383520 ).
[METHODS] An anti-GPC3 antigen-binding fragment (Fab) was generated under Good Manufacturing Practice conditions and labeled with Gallium-68 (Ga) to obtain [Ga]Ga-aGPC3-Fab. In vitro assays, small-animal PET/CT scans, and ex vivo biodistribution experiments were conducted to examine its GPC3 targeting ability. Five patients with radiologically suspected or diagnosed HCC were enrolled in a pilot clinical study and underwent [Ga]Ga-aGPC3-Fab PET imaging. Radiotracer uptake in tumor and non-tumor tissues was quantitatively analyzed.
[RESULTS] [Ga]Ga-aGPC3-Fab was synthesized with high radiochemical purity and demonstrated strong affinity and efficient internalization in GPC3-positive cells. It enabled clear tumor visualization in both subcutaneous and orthotopic GPC3-positive HCC mouse models. All five patients tolerated the PET procedure well, with no adverse effects. [Ga]Ga-aGPC3-Fab successfully detected intrahepatic metastases approximately 1 cm in diameter with high imaging contrast, including lesions that missed on magnetic resonance imaging.
[CONCLUSION] [Ga]Ga-aGPC3-Fab demonstrated a favorable safety profile and enabled effective visualization of GPC3-positive lesions. It may serve as a complementary approach to conventional imaging to improve the diagnostic accuracy of HCC.
[CLINICAL TRIAL REGISTRATION] ClinicalTrials.gov, NCT06383520. Registered on April 25, 2024 ( https://clinicaltrials.gov/study/NCT06383520 ).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Glypicans
- Carcinoma
- Hepatocellular
- Liver Neoplasms
- Humans
- Animals
- Positron Emission Tomography Computed Tomography
- Mice
- Male
- Female
- Translational Research
- Biomedical
- Middle Aged
- Gallium Radioisotopes
- Tissue Distribution
- Aged
- Cell Line
- Tumor
- Antigen-binding fragment
- Glypican-3
- Hepatocellular carcinoma
- Immuno-positron emission tomography
- Nuclear medicine
같은 제1저자의 인용 많은 논문 (5)
- Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.
- Integrated bulk and single-cell transcriptomics with experimental validation to identify calmodulin-related prognostic genes in lung adenocarcinoma.
- Bibliometric analysis of research trends and collaboration patterns in cardio-oncology focusing on lung cancer and heart failure.
- Glypican-3-Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside.
- Advancements in nanomedicine for the therapeutic regulation of efferocytosis: opportunities and challenges.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Key Considerations for Targeting in Pancreatic Cancer: Potential Impact on the Treatment Paradigm.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- Effective use of PROs for survival prediction: Transformer-based modelling in NSCLC patients.
- Combining network pharmacology and experimental validation to study the action and mechanism of brusatol against lung adenocarcinoma.
- Acquired L858R mutation following -TKI resistance in lung adenocarcinoma: a case report.